Get Your Lost Erection Back with Sildenafil Citrate 100mg

Erectile dysfunction (ED) is a sick and naughty male sexual dysfunction to have.  Because of this condition, it inhibits you from having successful intercourse with your female partner.  This is because without an erection, vaginal penetration is not possible.  Fortunately, although only temporary, you can get your erection back using sildenafil citrate 100mg.  Sildenafil citrate 100mg is very effective in providing you the erection you lost due to erectile dysfunction as it is the generic alternative of Viagra, the most popular and highly sought after ED treatment drug.

Sildenafil citrate 100mg is classified as a PDE5 inhibitor drug because it follows the same mechanism of action of drugs belonging to that class.  What PDE5 inhibitor drugs do is that it selectively focuses on the smooth muscles lining the penis.  This smooth muscle relaxes when you are sexually stimulated to allow blood to enter the cavities within the penis so an erection can be achieved.  Once you are no longer sexually aroused, the smooth muscles then contracts back to squeeze the blood out of the penis so the penis becomes limp again.  This is actually what is great about PDE5 inhibitor drugs like sildenafil citrate 100mg because they provide you with a normal-like erection function. Read more…

Future looks bleak for Avandia as safety trial put on hold

Last week saw an rule that there is reason to believe the troubled diabetes drug Avandia (rosiglitazone) does indeed increase cardiovascular risks compared to its direct competitor Actos (pioglitazone).

Now, the FDA appears to be moving to shut down the Canadian-led trial that represented the last chance for maker GlaxoSmithKline to prove its drug is safe. The agency put a "partial clinical hold" on new recruitment for the trial while it updates the lead investigators - Drs Salim Yusef and Hertzel Gerstein of McMaster University - on the results of last week's panel meeting.

While the FDA safety panel stopped short of voting to remove Avandia from the market, the agency can still take action without a vote, and most observers suspect the end is near for Avandia, which has already seen sales collapse in the wake of data suggesting it increases cardiovascular events.

In fact, the same safety concerns were inhibiting recruitment to the TIDE trial. GSK, which agreed in 2007 to fund a head-to-head comparison with pioglitazone, said last week that only 1,100 of an intended 16,000 study participants have volunteered to date.

1 comments:

sharon(aka Purley Quirt ) said...

I would like to see/know who is behind the thrust to use diabetes medication as a prophylactic measure ( including insulin).

Is this ever increasing drug dependent society ( at every level) ever going to ask who is behind it?

I am very intrigued by this new push by pharmacia to make physicians feel the time they spend on alternates to drugs ( teaching, training, lifestyle change)is a sign of ? failing to serve the best interests of the patient .